What does the evidence say about NAC Respiratory Randomized Trial?

Updated May 2026

Quick Answer

NAC Respiratory Randomized Trial has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: Results Patients treated with NAC nano-spray demonstrated a significant reduction in WHO mucositis grades and significantly improved OHIP-14 scores compared with the control group (p Conclusions N-acetylcysteine nano-spray appears to be an effective therapeutic option for the management of RIOM, reducing mucositis severity and improving quality of life in oral cancer patients.

Key Takeaways

  • 01Results Patients treated with NAC nano-spray demonstrated a significant reduction in WHO mucositis grades and significantly improved OHIP-14 scores compared with the control group (p Conclusions N-acetylcysteine nano-spray appears to be an effective therapeutic option for the management of RIOM, reducing mucositis severity and improving quality of life in oral cancer patients. [Essam A (2026)]
  • 02Background Radiation-induced oral mucositis (RIOM) is a common and debilitating complication of radiotherapy in oral cancer patients, significantly impairing quality of life and potentially interrupting treatment. [Essam A (2026)]
  • 03This study evaluated the therapeutic efficacy of N-acetylcysteine (NAC) nano-spray in managing RIOM, with particular emphasis on mucositis severity, quality of life, and serum gastrin-17 levels. [Essam A (2026)]
  • 04Clinically, it is the standard antidote for acetaminophen (APAP) overdose, restoring hepatic glutathione (GSH) and preventing or mitigating drug-induced liver injury and lowering risk of acute liver failure when administered within the ideal time window.It is also approved as a mucolytic in respiratory disease. [Qu Hui-Qi (2026)]
The current Migaku evidence database contains 2 reusable source documents for NAC Respiratory Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Results Patients treated with NAC nano-spray demonstrated a significant reduction in WHO mucositis grades and significantly improved OHIP-14 scores compared with the control group (p Conclusions N-acetylcysteine nano-spray appears to be an effective therapeutic option for the management of RIOM, reducing mucositis severity and improving quality of life in oral cancer patients. [Essam A (2026); evidence level 2] - Background Radiation-induced oral mucositis (RIOM) is a common and debilitating complication of radiotherapy in oral cancer patients, significantly impairing quality of life and potentially interrupting treatment. [Essam A (2026); evidence level 2] - This study evaluated the therapeutic efficacy of N-acetylcysteine (NAC) nano-spray in managing RIOM, with particular emphasis on mucositis severity, quality of life, and serum gastrin-17 levels. [Essam A (2026); evidence level 2] - Clinically, it is the standard antidote for acetaminophen (APAP) overdose, restoring hepatic glutathione (GSH) and preventing or mitigating drug-induced liver injury and lowering risk of acute liver failure when administered within the ideal time window.It is also approved as a mucolytic in respiratory disease. [Qu Hui-Qi (2026); evidence level 3] - In this review, these indicators are used only to illustrate the scale and diversification of NAC-related research activity, whereas assessment of therapeutic relevance rests primarily on mechanistic evidence and clinical studies. [Qu Hui-Qi (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. N-acetylcysteine nano-spray versus conventional treatment in the management of radiotherapy-induced oral mucositis in oral cancer patients: a randomized clinical trial.
  2. Redefining the role of the thiol-based agent N -acetylcysteine in human health and disease and elucidating potential advantages of its amide derivative